Abatacept SC
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sjögren's Syndrome
Conditions
Sjögren's Syndrome
Trial Timeline
Aug 1, 2014 → Aug 1, 2019
NCT ID
NCT02067910About Abatacept SC
Abatacept SC is a phase 3 stage product being developed by Bristol Myers Squibb for Sjögren's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02067910. Target conditions include Sjögren's Syndrome.
What happened to similar drugs?
0 of 7 similar drugs in Sjögren's Syndrome were approved
Approved (0) Terminated (1) Active (6)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02067910 | Phase 3 | Completed |
Competing Products
20 competing products in Sjögren's Syndrome